MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
Amgen India investment totals $200 million through 2025
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
IMCD India’s innovative formulations bring the Skinification trend to life with cutting-edge solutions across beauty and personal care
Theatre (OTs) dedicated to cataract, LASIK, and retina treatments added to meet the growing demand
Subscribe To Our Newsletter & Stay Updated
